碘克沙醇在高危患者造影中的安全性  被引量:6

Safety of Iodixanol for High Risk Patients Undergoing Coronary Arteriongraphy

在线阅读下载全文

作  者:邓增潮[1] 陈华栋[1] 梁增杰[1] 李坤浪[1] 

机构地区:[1]广东省高州市人民医院,广东高州525200

出  处:《中国医院用药评价与分析》2013年第4期368-370,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘  要:目的:观察碘克沙醇用于高危患者造影诊疗的安全性。方法:收集2012年5—12月心血管内科收治患糖尿病且血清肌酐水平增高的高危患者124例,应用随机数字表法分为观察组(62例)和对照组(62例),观察组采用碘克沙醇进行冠状动脉造影诊疗,对照组采用碘普罗胺进行冠状动脉造影诊疗,观察2组患者血清肌酐水平及不良反应发生情况。结果:造影后患者血清肌酐水平增高>44.2μmol/L方面,观察组(2例)明显低于对照组(15例),且观察组不良反应更小。结论:碘克沙醇用于高危患者的冠状动脉介入诊疗能明显减少对比剂肾病不良反应/事件的发生,安全性好。OBJECTIVE: To investigate the safety of iodixanol for high risk patients undergoing contrast examination. METHODS: From May 2012 to Oct. 2012, a total of 124 high risk patients with diabetes mellitus and higher serum creatinine levels admitted to the vasculocardiology department of our hospital were randomly divided into two groups using random digits table with 36 in each, the observation group and the control group. The observation group underwent coronary angiography using iodixanol for diagnosis and treatment, and the control group underwent coronary angiography using iopromide for diagnosis and treatment, with serum creatinine levels and side effects in the 2 groups observed. RESULTS : After undergoing angiography, regarding creatinine level increased to 〉 44.2 μmol/L, there were significantly far less cases in the observation group was than that in the control group (2 cases vs. 15 cases), and the observation group shower milder side effect compared with the control group. CONCLUSION: Compared with iopromide, iodixanol used for coronary artery intervention in patients at high risk resulted in significant reduction in the incidence of adverse drug reaction/adverse drug event such as contrast medium-induced nephropathy and it was proved to be of good safety.

关 键 词:碘克沙醇 造影检查 疗效 安全性 

分 类 号:R981.1[医药卫生—药品]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象